FLT3 and acute myeloid leukemia: Among patients in ELN favorable-risk (CN-AML patients carrying NPM1mutwithout FLT3-ITD and/or CEBPAdouble mut), the combined ORs for CR rate were 0.460 (95%CI: 0.252–0.840; P = 0.011; heterogeneity: I2 = 0.0%, P = 0.405; Fig. 4a).